HLUN-B Stock Analysis: H Lundbeck | CO
Drug Manufacturers - Specialty & Generic | CO, Denmark | Market Cap: 42.226m DKK | 12M Return: 2.8% | DK0061804770 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.7M
EPS Trend: 90.4%
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
H. Lundbeck A/S is a Denmark-based pharmaceutical company founded in 1915 and headquartered in Valby. It is focused on the research, development, manufacturing, and commercialization of treatments for psychiatric and neurological disorders, operating across Europe, the United States, and other international markets. The pharmaceutical sector is characterized by long development cycles and heavy reliance on patent-protected blockbuster drugs, with revenue concentration in a small number of key products.
The companys commercial portfolio spans several major therapeutic areas and includes Abilify Maintena / Abilify Asimtufii (schizophrenia and bipolar I disorder), Brintellix / Trintellix (depressive disorders), Rexulti / Rxulti (major depressive disorder and schizophrenia), Vyepti (migraine prevention), and Cipralex / Lexapro (depression), along with treatments for epilepsy, Parkinsons disease, dementia, and other neurological conditions.
Lundbeck maintains a broad clinical pipeline with candidates across phases 1 through 3, covering migraine, Parkinsons disease, neurohormonal dysfunctions, and developmental and epileptic encephalopathies. The company also holds a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for serious neurological conditions. The pipeline-heavy business model is typical of mid-cap pharmaceutical firms, where future growth depends on successful drug launches to offset patent expirations on existing products.
- Rexulti and Trintellix drive CNS franchise revenue growth
- Vyepti migraine prevention accelerates US sales trajectory
- Pipeline readouts in synucleinopathies and PTSD support expansion
| Net Income: 3.88b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.29 > 1.0 |
| NWC/Revenue: 13.40% < 20% (prev 19.07%; Δ -5.67% < -1%) |
| CFO/TA 0.10 > 3% & CFO 5.21b > Net Income 3.88b |
| Net Debt (7.68b) to EBITDA (8.25b): 0.93 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (992.1m) vs 12m ago -0.37% < -2% |
| Gross Margin: 78.27% > 18% (prev 81.55%; Δ -3.27% > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 45.40%; Δ 3.66% > 0%) |
| Interest Coverage Ratio: 20.21 > 6 (EBIT TTM 5.86b / Interest Expense TTM 290.0m) |
| A: 0.07 (Total Current Assets 12.8b - Total Current Liabilities 9.37b) / Total Assets 52.7b |
| B: 0.50 (Retained Earnings 26.2b / Total Assets 52.7b) |
| C: 0.11 (EBIT TTM 5.86b / Avg Total Assets 52.3b) |
| D: 1.04 (Book Value of Equity 26.9b / Total Liabilities 25.8b) |
| Altman-Z'' = 3.89 = AA |
| DSRI: 1.04 (Receivables 6.23b/5.48b, Revenue 25.6b/23.5b) |
| GMI: 1.04 (GM 81.55% / 78.27%) |
| AQI: 0.99 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.09 (Revenue 25.6b / 23.5b) |
| TATA: -0.03 (NI 3.88b - CFO 5.21b) / TA 52.7b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at DKK 45.26 with a total of 892,761 shares traded. Over the past week, the price has changed by +6.34%, over one month by +6.04%, over three months by +5.55% and over the past year by +2.76%.
Current recommended Stop Loss: 43.60 (which is 3.7% or 1.4 ATR below the current price).
H Lundbeck has no consensus analysts rating.
P/E Trailing = 10.7204
P/E Forward = 10.5597
P/S = 1.6266
P/B = 1.5751
P/EG = 8.0471
Revenue TTM = 25.6b DKK
EBIT TTM = 5.86b DKK
EBITDA TTM = 8.25b DKK
Long Term Debt = 8.96b DKK (from longTermDebt, last quarter)
Short Term Debt = 71.0m DKK (from shortTermDebt, last quarter)
Debt = 9.88b DKK (from shortLongTermDebtTotal, last quarter) + Leases 462.0m
Net Debt = 7.68b DKK (calculated: Debt 9.88b - CCE 2.20b)
Enterprise Value = 49.9b DKK (42.2b + Debt 9.88b - CCE 2.20b)
Interest Coverage Ratio = 20.21 (Ebit TTM 5.86b / Interest Expense TTM 290.0m)
EV/FCF = 10.76x (Enterprise Value 49.9b / FCF TTM 4.64b)
FCF Yield = 9.29% (FCF TTM 4.64b / Enterprise Value 49.9b)
FCF Margin = 18.09% (FCF TTM 4.64b / Revenue TTM 25.6b)
Net Margin = 15.13% (Net Income TTM 3.88b / Revenue TTM 25.6b)
Gross Margin = 78.27% ((Revenue TTM 25.6b - Cost of Revenue TTM 5.57b) / Revenue TTM)
Gross Margin QoQ = 79.00% (prev 80.03%)
Tobins Q-Ratio = 0.95 (Enterprise Value 49.9b / Total Assets 52.7b)
Interest Expense / Debt = 2.94% (Interest Expense 290.0m / Debt 9.88b)
Taxrate = 27.73% (1.49b / 5.37b)
NOPAT = 4.23b (EBIT 5.86b * (1 - 27.73%))
Current Ratio = 1.37 (Total Current Assets 12.8b / Total Current Liabilities 9.37b)
Debt / Equity = 0.37 (Debt 9.88b / totalStockholderEquity, last quarter 26.9b)
Debt / EBITDA = 0.93 (Net Debt 7.68b / EBITDA 8.25b)
Debt / FCF = 1.66 (Net Debt 7.68b / FCF TTM 4.64b)
Total Stockholder Equity = 25.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.43% (Net Income 3.88b / Total Assets 52.7b)
RoE = 15.13% (Net Income TTM 3.88b / Total Stockholder Equity 25.6b)
RoCE = 16.94% (EBIT 5.86b / Capital Employed (Equity 25.6b + L.T.Debt 8.96b))
RoIC = 10.05% (NOPAT 4.23b / Invested Capital 42.1b)
WACC = 6.87% (E(42.2b)/V(52.1b) * Re(7.98%) + D(9.88b)/V(52.1b) * Rd(2.94%) * (1-Tc(0.28)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.54 | Cagr: 0.01%
[DCF] Terminal Value 77.97% ; FCFF base≈3.92b ; Y1≈4.50b ; Y5≈6.62b
[DCF] Fair Price = 115.9 (EV 99.6b - Net Debt 7.68b = Equity 91.9b / Shares 793.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.37 | EPS CAGR: 20.99% | SUE: 0.20 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 10.97% | SUE: 1.32 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.56 | Chg30d=+1.02% | Revisions=+17% | Analysts=5
EPS current Year (2026-12-31): EPS=6.33 | Chg30d=-0.07% | Revisions=-12% | GrowthEPS=+20.3% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=6.19 | Chg30d=+0.85% | Revisions=+0% | GrowthEPS=-2.2% | GrowthRev=+0.5%
[Analyst] Revisions Ratio: +0% (up=7, down=7)